Dr. Alon Friedman is the founder and CEO of Emagix and is a Professor of Neuroscience at Dalhousie and Ben-Gurion Universities. He completed his medical and doctoral training at Ben-Gurion University, followed by a neurosurgery residency at Soroka University Medical Center in Israel. His post-doctoral training was conducted at the Charitè Medical University in Berlin, Germany, as an Alexander von-Humboldt fellow. Dr. Friedman has been studying microvascular pathologies for the past 15 years and has published over 130 peer-reviewed publications. Dr. Friedman’s research has revealed major insights into the role of microvascular dysfunction in diseases of the eye and the brain, and has established novel AI-based tools for reliable detection of microvascular abnormalities. In 2016, Dr. Friedman founded Emagix with the goal to translate these new AI technologies into clinical use. Emagix’s first product – RetiCAD, is designed to help ophthalmologists detect the vascular abnormalities of diabetic retinopathy in order to help prevent blindness is patients with diabetes. Dr. Friedman is excited to collaborate with ophthalmologists, clinicians caring for patients with diabetes, and researchers in the field.